PURPOSE: Epigenetic age acceleration (EAA) is robustly linked with mortality and morbidity. This study examined risk factors of EAA and its association with overall survival (OS), progression-free survival (PFS), and quality of life (QOL) in patients with head and neck cancer (HNC) receiving radiation therapy. METHODS AND MATERIALS: Patients without distant metastasis were enrolled and followed before and at the end of radiation therapy and at 6 and 12 months after radiation therapy. EAA was calculated with DNAmPhenoAge at all 4 time points. Risk factors included demographic characteristics, lifestyle, clinical characteristics, treatment-related symptoms, and blood biomarkers. Survival data were collected until August 2020, and QOL was measured using Functional Assessment of Cancer Therapy-HNC. RESULTS: Increased comorbidity, symptoms unrelated to human papilloma virus, and more severe treatment-related symptoms were associated with higher EAA (P = .03 to P < .001). A nonlinear association (quadratic) between body mass index (BMI) and EAA was observed: decreased BMI (<35 kg/m2; P = .04) and increased BMI (≥35 kg/m2; P = .01) were linked to higher EAA. Increased EAA (per year) was associated with worse OS (hazard ratio [HR], 1.11 [95% confidence interval {CI}, 1.03-1.18; P = .004]; HR, 1.10 [95% CI, 1.01-1.19; P = .02] for EAA at 6 and 12 months after treatment, respectively) and PFS (HR, 1.10 [95% CI, 1.02-1.19; P = .02]; HR, 1.14 [95% CI, 1.06-1.23; P < .001]; and HR, 1.08 [95% CI, 1.02-1.14; P = .01]) for EAA before, immediately after, and 6 months after radiation therapy, respectively) and QOL over time (β = -0.61; P = .001). An average of 3.25 to 3.33 years of age acceleration across time, which was responsible for 33% to 44% higher HRs of OS and PFS, was observed in those who died or developed recurrence compared with those who did not (all P < .001). CONCLUSIONS: Compared with demographic and lifestyle factors, clinical characteristics were more likely to contribute to faster biological aging in patients with HNC. Acceleration in epigenetic age resulted in more aggressive adverse events, including OS and PFS. EAA could be considered as a marker for cancer outcomes, and decelerating aging could improve survival and QOL.
PURPOSE: Epigenetic age acceleration (EAA) is robustly linked with mortality and morbidity. This study examined risk factors of EAA and its association with overall survival (OS), progression-free survival (PFS), and quality of life (QOL) in patients with head and neck cancer (HNC) receiving radiation therapy. METHODS AND MATERIALS: Patients without distant metastasis were enrolled and followed before and at the end of radiation therapy and at 6 and 12 months after radiation therapy. EAA was calculated with DNAmPhenoAge at all 4 time points. Risk factors included demographic characteristics, lifestyle, clinical characteristics, treatment-related symptoms, and blood biomarkers. Survival data were collected until August 2020, and QOL was measured using Functional Assessment of Cancer Therapy-HNC. RESULTS: Increased comorbidity, symptoms unrelated to human papilloma virus, and more severe treatment-related symptoms were associated with higher EAA (P = .03 to P < .001). A nonlinear association (quadratic) between body mass index (BMI) and EAA was observed: decreased BMI (<35 kg/m2; P = .04) and increased BMI (≥35 kg/m2; P = .01) were linked to higher EAA. Increased EAA (per year) was associated with worse OS (hazard ratio [HR], 1.11 [95% confidence interval {CI}, 1.03-1.18; P = .004]; HR, 1.10 [95% CI, 1.01-1.19; P = .02] for EAA at 6 and 12 months after treatment, respectively) and PFS (HR, 1.10 [95% CI, 1.02-1.19; P = .02]; HR, 1.14 [95% CI, 1.06-1.23; P < .001]; and HR, 1.08 [95% CI, 1.02-1.14; P = .01]) for EAA before, immediately after, and 6 months after radiation therapy, respectively) and QOL over time (β = -0.61; P = .001). An average of 3.25 to 3.33 years of age acceleration across time, which was responsible for 33% to 44% higher HRs of OS and PFS, was observed in those who died or developed recurrence compared with those who did not (all P < .001). CONCLUSIONS: Compared with demographic and lifestyle factors, clinical characteristics were more likely to contribute to faster biological aging in patients with HNC. Acceleration in epigenetic age resulted in more aggressive adverse events, including OS and PFS. EAA could be considered as a marker for cancer outcomes, and decelerating aging could improve survival and QOL.
Authors: Cathy Ndiaye; Marisa Mena; Laia Alemany; Marc Arbyn; Xavier Castellsagué; Louise Laporte; F Xavier Bosch; Silvia de Sanjosé; Helen Trottier Journal: Lancet Oncol Date: 2014-10-16 Impact factor: 41.316
Authors: Jennifer L Guida; Tanya Agurs-Collins; Tim A Ahles; Judith Campisi; William Dale; Wendy Demark-Wahnefried; Jorg Dietrich; Rebecca Fuldner; Lisa Gallicchio; Paige A Green; Arti Hurria; Michelle C Janelsins; Chamelli Jhappan; James L Kirkland; Ronald Kohanski; Valter Longo; Simin Meydani; Supriya Mohile; Laura J Niedernhofer; Christian Nelson; Frank Perna; Keri Schadler; Jessica M Scott; Jennifer A Schrack; Russell P Tracy; Jan van Deursen; Kirsten K Ness Journal: J Natl Cancer Inst Date: 2021-02-01 Impact factor: 13.506
Authors: Brian H Chen; Riccardo E Marioni; Elena Colicino; Marjolein J Peters; Cavin K Ward-Caviness; Pei-Chien Tsai; Nicholas S Roetker; Allan C Just; Ellen W Demerath; Weihua Guan; Jan Bressler; Myriam Fornage; Stephanie Studenski; Amy R Vandiver; Ann Zenobia Moore; Toshiko Tanaka; Douglas P Kiel; Liming Liang; Pantel Vokonas; Joel Schwartz; Kathryn L Lunetta; Joanne M Murabito; Stefania Bandinelli; Dena G Hernandez; David Melzer; Michael Nalls; Luke C Pilling; Timothy R Price; Andrew B Singleton; Christian Gieger; Rolf Holle; Anja Kretschmer; Florian Kronenberg; Sonja Kunze; Jakob Linseisen; Christine Meisinger; Wolfgang Rathmann; Melanie Waldenberger; Peter M Visscher; Sonia Shah; Naomi R Wray; Allan F McRae; Oscar H Franco; Albert Hofman; André G Uitterlinden; Devin Absher; Themistocles Assimes; Morgan E Levine; Ake T Lu; Philip S Tsao; Lifang Hou; JoAnn E Manson; Cara L Carty; Andrea Z LaCroix; Alexander P Reiner; Tim D Spector; Andrew P Feinberg; Daniel Levy; Andrea Baccarelli; Joyce van Meurs; Jordana T Bell; Annette Peters; Ian J Deary; James S Pankow; Luigi Ferrucci; Steve Horvath Journal: Aging (Albany NY) Date: 2016-09-28 Impact factor: 5.682
Authors: Austin Quach; Morgan E Levine; Toshiko Tanaka; Ake T Lu; Brian H Chen; Luigi Ferrucci; Beate Ritz; Stefania Bandinelli; Marian L Neuhouser; Jeannette M Beasley; Linda Snetselaar; Robert B Wallace; Philip S Tsao; Devin Absher; Themistocles L Assimes; James D Stewart; Yun Li; Lifang Hou; Andrea A Baccarelli; Eric A Whitsel; Steve Horvath Journal: Aging (Albany NY) Date: 2017-02-14 Impact factor: 5.682
Authors: Yinan Zheng; Brian T Joyce; Elena Colicino; Lei Liu; Wei Zhang; Qi Dai; Martha J Shrubsole; Warren A Kibbe; Tao Gao; Zhou Zhang; Nadereh Jafari; Pantel Vokonas; Joel Schwartz; Andrea A Baccarelli; Lifang Hou Journal: EBioMedicine Date: 2016-02-08 Impact factor: 8.143
Authors: Morgan E Levine; H Dean Hosgood; Brian Chen; Devin Absher; Themistocles Assimes; Steve Horvath Journal: Aging (Albany NY) Date: 2015-09 Impact factor: 5.682
Authors: Yufen Lin; Deborah W Bruner; Sudeshna Paul; Andrew H Miller; Nabil F Saba; Kristin A Higgins; Dong M Shin; Wenhui Zhang; Christine Miaskowski; Canhua Xiao Journal: Cancer Date: 2022-08-15 Impact factor: 6.921